Update from the GHMonitorSM observational registry in children treated with recombinant human growth hormone (Saizen®)

Leslie Plotnick, Robert Rapaport, Paul Desrosiers, John Fuqua

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Since 2003, the GH MonitorsmSM, an observational registry, has collected data on pediatric subjects treated with Saizen® (recombinant human growth hormone (r-hGH)) in the United States and Canada. This article provides an update on the demographic characteristics of subjects enrolled in the GHMonitorSM Registry. As of August 2007, 1733 subjects were enrolled (68.9% male). The most common primary diagnosis at screening was idiopathic growth hormone deficiency (56.5% of subjects). Of those subjects with available data, mean height standard deviation (SD) score was -2.1±1.0, mean weight SD score was -1.4±1.5, and mean body mass index SD score was -0.1±1.3. Among subjects in whom the presence or absence of other pituitary hormone deficiencies was recorded, 16.1% had multiple pituitary hormone deficiencies. Most patients reported high compliance with therapy (92.6% missed 0-3 doses per month); compliance was similar for all delivery devices (needle Isyringe, cool.click™ or one.click™) used. Two serious adverse events related to Saizen® (hospitalization for placement of right frontal ventriculostomy and right frontal craniotomy for tronscallosal resection of a large recurrent craniopharyngioma and left slipped copitofemoral epiphysis that required pinning of the right hip) were reported in the period from August 2006 to August 2007. This update of the GHMonitorSM Registry continues to provide insight into the characteristics of children treated with this agent and continued evidence of the efficacy and safety of Saizen® in children.

Original languageEnglish
Pages (from-to)278-282
Number of pages5
JournalPediatric Endocrinology Reviews
Volume6
Issue numberSUPPL. 2
StatePublished - Jan 2009

Fingerprint

Human Growth Hormone
Growth Hormone
Registries
Pituitary Hormones
Slipped Epiphyses
Ventriculostomy
Craniopharyngioma
Craniotomy
Compliance
Canada
Needles
Hip
Hospitalization
Body Mass Index
Demography
Pediatrics
Safety
Weights and Measures
Equipment and Supplies
Therapeutics

Keywords

  • Dose
  • GHMonitor
  • Gonadal steroid hormones
  • Growth hormone
  • Growth hormone deficiency
  • Pituitary hormone deficiency

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Cite this

Update from the GHMonitorSM observational registry in children treated with recombinant human growth hormone (Saizen®). / Plotnick, Leslie; Rapaport, Robert; Desrosiers, Paul; Fuqua, John.

In: Pediatric Endocrinology Reviews, Vol. 6, No. SUPPL. 2, 01.2009, p. 278-282.

Research output: Contribution to journalArticle

@article{8cd04af939a44c869cfc93a6b6fe12e5,
title = "Update from the GHMonitorSM observational registry in children treated with recombinant human growth hormone (Saizen{\circledR})",
abstract = "Since 2003, the GH MonitorsmSM, an observational registry, has collected data on pediatric subjects treated with Saizen{\circledR} (recombinant human growth hormone (r-hGH)) in the United States and Canada. This article provides an update on the demographic characteristics of subjects enrolled in the GHMonitorSM Registry. As of August 2007, 1733 subjects were enrolled (68.9{\%} male). The most common primary diagnosis at screening was idiopathic growth hormone deficiency (56.5{\%} of subjects). Of those subjects with available data, mean height standard deviation (SD) score was -2.1±1.0, mean weight SD score was -1.4±1.5, and mean body mass index SD score was -0.1±1.3. Among subjects in whom the presence or absence of other pituitary hormone deficiencies was recorded, 16.1{\%} had multiple pituitary hormone deficiencies. Most patients reported high compliance with therapy (92.6{\%} missed 0-3 doses per month); compliance was similar for all delivery devices (needle Isyringe, cool.click™ or one.click™) used. Two serious adverse events related to Saizen{\circledR} (hospitalization for placement of right frontal ventriculostomy and right frontal craniotomy for tronscallosal resection of a large recurrent craniopharyngioma and left slipped copitofemoral epiphysis that required pinning of the right hip) were reported in the period from August 2006 to August 2007. This update of the GHMonitorSM Registry continues to provide insight into the characteristics of children treated with this agent and continued evidence of the efficacy and safety of Saizen{\circledR} in children.",
keywords = "Dose, GHMonitor, Gonadal steroid hormones, Growth hormone, Growth hormone deficiency, Pituitary hormone deficiency",
author = "Leslie Plotnick and Robert Rapaport and Paul Desrosiers and John Fuqua",
year = "2009",
month = "1",
language = "English",
volume = "6",
pages = "278--282",
journal = "Pediatric Endocrinology Reviews",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Update from the GHMonitorSM observational registry in children treated with recombinant human growth hormone (Saizen®)

AU - Plotnick, Leslie

AU - Rapaport, Robert

AU - Desrosiers, Paul

AU - Fuqua, John

PY - 2009/1

Y1 - 2009/1

N2 - Since 2003, the GH MonitorsmSM, an observational registry, has collected data on pediatric subjects treated with Saizen® (recombinant human growth hormone (r-hGH)) in the United States and Canada. This article provides an update on the demographic characteristics of subjects enrolled in the GHMonitorSM Registry. As of August 2007, 1733 subjects were enrolled (68.9% male). The most common primary diagnosis at screening was idiopathic growth hormone deficiency (56.5% of subjects). Of those subjects with available data, mean height standard deviation (SD) score was -2.1±1.0, mean weight SD score was -1.4±1.5, and mean body mass index SD score was -0.1±1.3. Among subjects in whom the presence or absence of other pituitary hormone deficiencies was recorded, 16.1% had multiple pituitary hormone deficiencies. Most patients reported high compliance with therapy (92.6% missed 0-3 doses per month); compliance was similar for all delivery devices (needle Isyringe, cool.click™ or one.click™) used. Two serious adverse events related to Saizen® (hospitalization for placement of right frontal ventriculostomy and right frontal craniotomy for tronscallosal resection of a large recurrent craniopharyngioma and left slipped copitofemoral epiphysis that required pinning of the right hip) were reported in the period from August 2006 to August 2007. This update of the GHMonitorSM Registry continues to provide insight into the characteristics of children treated with this agent and continued evidence of the efficacy and safety of Saizen® in children.

AB - Since 2003, the GH MonitorsmSM, an observational registry, has collected data on pediatric subjects treated with Saizen® (recombinant human growth hormone (r-hGH)) in the United States and Canada. This article provides an update on the demographic characteristics of subjects enrolled in the GHMonitorSM Registry. As of August 2007, 1733 subjects were enrolled (68.9% male). The most common primary diagnosis at screening was idiopathic growth hormone deficiency (56.5% of subjects). Of those subjects with available data, mean height standard deviation (SD) score was -2.1±1.0, mean weight SD score was -1.4±1.5, and mean body mass index SD score was -0.1±1.3. Among subjects in whom the presence or absence of other pituitary hormone deficiencies was recorded, 16.1% had multiple pituitary hormone deficiencies. Most patients reported high compliance with therapy (92.6% missed 0-3 doses per month); compliance was similar for all delivery devices (needle Isyringe, cool.click™ or one.click™) used. Two serious adverse events related to Saizen® (hospitalization for placement of right frontal ventriculostomy and right frontal craniotomy for tronscallosal resection of a large recurrent craniopharyngioma and left slipped copitofemoral epiphysis that required pinning of the right hip) were reported in the period from August 2006 to August 2007. This update of the GHMonitorSM Registry continues to provide insight into the characteristics of children treated with this agent and continued evidence of the efficacy and safety of Saizen® in children.

KW - Dose

KW - GHMonitor

KW - Gonadal steroid hormones

KW - Growth hormone

KW - Growth hormone deficiency

KW - Pituitary hormone deficiency

UR - http://www.scopus.com/inward/record.url?scp=65549096356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549096356&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 278

EP - 282

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

SN - 1565-4753

IS - SUPPL. 2

ER -